RBS2418
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for RBS2418, covering 2025-12-19 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma [Phase 2]